Overview

Pioglitazone for Idiopathic Gastroparesis

Status:
Recruiting

Trial end date:
2022-09-29

Target enrollment:

Participant gender:

Summary

The principal objective of this pilot study will be to evaluate whether 8 weeks of treatment of pioglitazone will improve symptoms as measured by the Gastrointestinal Symptom Index (GCSI) in patients with Idiopathic Gastroparesis.

Phase:

Early Phase 1

Details

Lead Sponsor:

Johns Hopkins University

Treatments:

Pioglitazone